120 / 154
446
23. Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype
on survival and the graded prognostic assessment for patients
with breast cancer and brain metastases. Int J Radiat Oncol Biol
Phys 2012;82:2111-7.
24. Johung KL, Yao X, Li F, et al. A clinical model for identifying
radiosensitive tumor genotypes in non-small cell lung cancer.
Clin Cancer Res 2013;19:5523-32.
25. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A
new prognostic index and comparison to three other indices
for patients with brain metastases: an analysis of 1,960
patients in the RTOG database. Int J Radiat Oncol Biol Phys
2008;70:510–4.
26. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of
surgery in the treatment of single metastases to the brain. N
Engl J Med 1990;322:494-500.
27. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of
single brain metastasis: radiotherapy alone or combined with
neurosurgery?. Ann Neurol 1993;33:583-90.
28. Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of
multiple brain metastases. J Neurosurg 1993;79:210-6.
29. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery
plus whole-brain radiation therapy vs stereotactic radiosurgery
alone for treatment of brain metastases: a randomized
controlled trial. JAMA 2006;295:2483-91.
30. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory
with conformal avoidance of the hippocampal neural stem-
cell compartment during whole-brain radiotherapy for brain
metastases (RTOG 0933): a phase II multi-institutional trial. J
Clin Oncol 2014;32:3810–6.
31. Kazda T, Jancalek R, Pospisil P, et al. Why and how to spare the
hippocampus during brain radiotherapy: the developing role of
hippocampal avoidance in cranial radiotherapy. Radiat Oncol
2014;9:139.
32. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention
of cognitive dysfunction in patients receiving whole-brain
radiotherapy: a randomized, double-blind, placebo-controlled
trial. Neuro-oncology 2013;15:1429-37.
33. Moraes FY, Taunk NK, Marta GN, Suh JH, Yamada Y. The rationale
for targeted therapies and stereotactic radiosurgery in the
treatment of brain metastases. Oncologist 2016;21:244–51.
34. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation
therapy with or without stereotactic radiosurgery boost for
patients with one to three brain metastases: phase III results of
the RTOG 9508 randomised trial. Lancet 2004;363:1665-72.
35. Brown P, Asher A, Ballman K, et al. NCCTG N0574 (Alliance):
A phase III randomized trial of whole brain radiation therapy
(WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3
brain metastases. J Clin Oncol 2015; 33, (suppl; abstr: LBA4).
36. Peak S, Abrey LE. Chemotherapy and the treatment of brain
metastases. Hematol Oncol Clin North Am 2006;20:1287-95.
37. Fabi A, Felici A, Metro G. Brain metastases from solid
tumors: disease outcome according to type of treatment and
therapeutic resources of the treating center. J Exp Clin Cancer
Res 2011;30:10.
38. Cancer Genome Atlas Research Network. Comprehensive
molecular profiling of lung adenocarcinoma. Nature
2014;511:543-50.
39. Kwak EL1, Bang YJ, Camidge DR, et al. Anaplastic lymphoma
kinase inhibition in non-small-cell lung cancer. N Engl J Med
2010;363:1693-703.
40. Cancer Genome Atlas Network. Genomic Classification of
Cutaneous Melanoma. Cell 2015;161:1681-96.
41. Cancer Genome Atlas Network. Comprehensive molecular
portraits of human breast tumours. Nature 2012;490
42. Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib
plus concurrent whole-brain radiation therapy for patients
with brain metastases from non-smallcell lung cancer. J Clin
Oncol 2013;31:895–902.
43. Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P. Phase II
study of whole brain radiotherapy with or without erlotinib
in patients with multiple brain metastases from lung
adenocarcinoma. Drug Des Dev Ther 2013;7:1179–86.
44. Fan Y,Huang Z, Fang L, et al. A phase II study of icotinib and
whole-brain radiotherapy in Chinese patients with brain
metastases from non-small cell lung cancer. Cancer Chemother
Pharmacol 2015;76:517–23.
45. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang
VL. Radiosurgery for melanoma brain metastases in the
ipilimumab era and the possibility of longer survival. J
Neurosurg 2012;117:227–33.
46. Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of
melanoma brain metastases treated with stereotactic radiation
and anti-PD-1 therapy. Ann Oncol 2016;27:434–41.
47. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of
enhanced radiation response following epidermal growth factor
receptor signaling inhibition by erlotinib (Tarceva). Cancer Res
2005;65:3328–35.
48. Postow MA, Callahan MK, Barker CA, et al. Immunologic
correlates of the abscopal effect in a patient with melanoma.
N Engl J Med 2012;366:925–31.
49. Bloy N, Pol J, Manic G, et al. Trial watch: radioimmunotherapy for
oncological indications. Oncoimmunology. 2014;3:e954929.
50. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining
radiotherapy and immunotherapy: a revived partnership. Int J
Radiat Oncol Biol Phys 2005;63:655–66.
51. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR.
Factors associated with the development of brain metastases:
analysis of 975 patients with early stage nonsmall cell lung
cancer. Cancer 2010;116:5038-46.
52. Consonni D, Pierobon M, Gail MH, et al. Lung cancer prognosis
before and after recurrence in a population-based setting. J.
Natl. Cancer Inst 2015;107:djv059.
53. Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth
factor receptor tyrosine kinase inhibitors for brain metastasis in
non-small cell lung cancer patients harboring either exon 19 or
21 mutation. Lung Cancer 2012;77:556–60.
54. Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid
concentration of erlotinib and its active metabolite OSI-420 in
[REV. MED. CLIN. CONDES - 2017; 28(3) 437-449]